Direct healthcare costs of glaucoma treatment

Rahman, Mustafizur; Beard, Stephen; Discombe, Russell; Sharma, Ranjana; Montgomery, Donald

doi:10.1136/bjophthalmol-2012-302525

Cited by 22 publications

(15 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glaucoma also contributes to significant direct and indirect healthcare costs [47–49]. Direct medical costs include ocular hypotensive drugs, physician, and hospital visits, as well as glaucoma-related procedures.…”

Section: Interpretation Of Recent Epidemiology Trendsmentioning

confidence: 99%

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Harasymowycz

Birt

Gooi

et al. 2016

Journal of Ophthalmology

100

View full text Add to dashboard Cite

Glaucoma is a medical term describing a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and retinal nerve fibre layer and resulting in changes in the optic nerve head. Glaucoma is a leading cause of irreversible vision loss worldwide. With the aging population it is expected that the prevalence of glaucoma will continue to increase. Despite recent advances in imaging and visual field testing techniques that allow establishment of earlier diagnosis and treatment initiation, significant numbers of glaucoma patients are undiagnosed and present late in the course of their disease. This can lead to irreversible vision loss, reduced quality of life, and a higher socioeconomic burden. Selection of therapeutic approaches for glaucoma should be based on careful ocular examination, patient medical history, presence of comorbidities, and awareness of concomitant systemic therapies. Therapy should also be individualized to patients' needs and preferences. Recent developments in this therapeutic field require revisiting treatment algorithms and integration of traditional and novel approaches in order to ensure optimal visual outcomes. This article provides an overview of recent developments and practice trends in the medical management of glaucoma in Canada. A discussion of the surgical management is beyond the scope of this paper.

show abstract

Section: Interpretation Of Recent Epidemiology Trendsmentioning

confidence: 99%

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Harasymowycz

Birt

Gooi

et al. 2016

Journal of Ophthalmology

100

View full text Add to dashboard Cite

show abstract

“…Developing countries reported some data which indicated that cost of surgical treatment in advanced stadium of glaucoma disease with postoperatively prescribed anti glaucomatous drugs is more expansive for the country, than medical therapy prescribed for medical treatment only (23). On the other hand, only successful surgical treatment, with postoperative IOP control, is cheaper than medical treatment (24). Non-drug costs (direct non-medical and indirect cost) accounted for 54%-66% of the overall treatment cost (25).…”

Section: Pharmacoeconomics Aspectsmentioning

confidence: 99%

Primary open-angle glaucoma and farmacoeconomics: Review

Sarenac-Vulovic

Janićijević

2016

SANAMED

View full text Add to dashboard Cite

Primary open-angle glaucoma (POAG) is defined as a chronic and progressive disease. Date suggested that it is the second most common cause of the blindness in the world. Blindness, as global problem, is partially consequences of poor health insurance, low medical education, etc. The only modifiable risk factor for glaucoma is intraocular pressure. Cost of the antiglaucomatous treatment increased by prescribing and using wide spectrum of antiglaucomatous drugs. If an ophthalmologist is not satisfied with glaucomatous disease control, need for the laser or surgical treatment is appeared. Disease stadium also determines the cost of the treatment. The social and economic burden of glaucoma can be changed by increased life expectancy, older population age and higher per capita GDP. Unique opinion about cost effectiveness cannot be reached, due to nonconforming findings of many studies. Treatment approach must be individualized to every patient, according to the disease's stadium, availability of therapeutic modalities and approaches, life expectancy and the level of GDP. Efficacy, compliance and potential side-effects of prescribed medication also determine the proper treatment choice.

show abstract

“…33 Non-drug costs (direct non-medical and indirect cost) accounted for 54%–66% of the overall treatment cost. 34 – 36 Direct non-medical costs include costs not directly related to medical treatment, such as transportation. The average transportation fee per clinic visit is US$16.7.…”

Section: Developing Nationsmentioning

confidence: 99%

“…Drug costs vary over time; unlike the normal inflationary pattern, drug costs typically remain stable or decline over time. 34 As the prostaglandin analogues become generic, their unit costs will be cheaper, hence making medical treatment even more favorable.…”

Section: Factors Affecting Pharmacoeconomic Evaluations Of Glaucoma Mmentioning

confidence: 99%

Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma

Ting¹,

Yim²,

Ng³

2014

CEOR

View full text Add to dashboard Cite

Glaucoma is the second highest cause of blindness worldwide with an estimated half of the glaucoma population unaware of their disease. To date, intraocular pressure is the most important modifiable risk factor and lowering it has been proven to reduce progression of visual field loss associated with glaucoma. Different strategies are available to lower intraocular pressure and include medical, laser, or surgical treatment in the form of topical or systemic medications, argon or selective laser trabeculoplasty, and glaucoma drainage surgery such as trabeculectomy, deep sclerectomy, or other drainage devices. The effectiveness of these treatments has been well documented however their cost-effectiveness between the developed world and third world remains unclear.

show abstract

Direct healthcare costs of glaucoma treatment

Abstract: This is the only study to directly assess the lifetime treatment costs of glaucoma. Awareness of the costs of glaucoma treatment may be of increased importance in these financially challenging times.

Cited by 22 publications

References 14 publications

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Primary open-angle glaucoma and farmacoeconomics: Review

Different strategies and cost-effectiveness in the treatment of primary open angle glaucoma

Contact Info

Product

Resources

About